Biomarkers for diseases with TDP-43 pathology
Section snippets
Diseases with TDP-43 pathology
The identification of hyper-phosphorylated and ubiquitinated TDP-43 as major component of aggregates forming the neuropathological hallmark of about 50% of FTLD cases and of 97% of ALS cases (Arai et al., 2006; Mackenzie et al., 2007; Maekawa et al., 2009; Neumann et al., 2006) initialized the research for biomarkers enabling for the detection of TDP-43 pathology in vivo, which is a prerequisite for etiology-specific treatment. Until now, there is no biomarker available that reliably indicates
TDP-43 pathology subtypes
Four histopathological subtypes of inclusions can be distinguished in TDP-43 proteinopathies using ubiquitin and TDP-43 antibodies, and recently a fifth subtype was published (Davidson et al., 2007; Lee et al., 2017; Mackenzie et al., 2006; Mackenzie et al., 2011; Sampathu et al., 2006). Types A and B are characterized by neuronal cytoplasmic inclusions (NCIs) located in superficial cortical layers and for type B also in deeper layers. In type A, additionally short dystrophic neurites (DNs)
Need for biomarkers for TDP-43 pathology/focus of review
To date, there is no biomarker available indicative of TDP-43 pathology at patients' lifetime. As the knowledge of the underlying pathology is a prerequisite of etiology-specific treatment, intensive research is going on to either establish methods for the detection of disease-associated TDP-43 or to identify neurochemical and imaging biomarkers reflecting the underlying pathology.
Here, we review the current status of research about biomarkers for TDP-43 proteinopathies with a focus on TDP-43
TDP-43 structure and function
For the first time the TDP-43 was first isolated in 1995 as a novel transcriptional inactivator of the HIV-1 gene expression by binding to the TAR element (Ou et al., 1995). In addition to transcriptional regulation, TDP-43 also plays a role in splicing regulation and mRNA stability (Buratti and Baralle, 2008). The 414 amino acid protein which belongs to the family of heterogeneous ribonuclear proteins has two RNA recognition motifs (RRM) with the preference to bind TG and UG nucleic acids (Kuo
Immuno-based techniques
Frequently used TDP-43 detection methods are antibody-based techniques. A systematic review of existing antibodies and ELISA for TDP-43 was published in 2015 (Goossens et al., 2015). The most commonly used ELISA to quantify TDP-43 in body fluids (Foulds et al., 2008; Foulds et al., 2009; Hosokawa et al., 2014; Kasai et al., 2009; Kuiperij et al., 2010; Noto et al., 2011; Verstraete et al., 2012) includes a monoclonal capture antibody (2E2-D3, Abnova) that targets within amino acids 205–222. For
Plasma and blood-derived cells
Several studies have analyzed TDP-43 in blood, since blood can be rapidly acquired in a minimally invasive manner and therefore is the preferential source for follow-up measurements. Studies that quantified TDP-43 in plasma and blood-derived cells are summarized in Table 1.
In 2008, TDP-43 was measured in plasma of FTD and AD patients for the first time (Foulds et al., 2008). Elevated TDP-43 plasma levels were detected in 46% FTD and 22% AD patients, conforming to the known proportions of TDP-43
TDP-43-unrelated fluid biomarkers
Until today, CSF biomarkers are not included in the diagnostic criteria for ALS or FTLD subgroups. The AD core biomarkers Aβ42, t-tau, and p-tau, can help to differentiate between AD and FTLD-TDP, especially in early disease stage. Furthermore, they might be useful in the differential diagnosis of FTLD subgroups. Beyond, biomarkers of neurodegeneration or neuronal dysfunction, especially neurofilaments, may assist diagnosis and were proposed to figure as biomarkers for severity of the disease
Imaging biomarkers
Structural and functional imaging is used with the aim to describe differences between TDP-43 and other proteinopathies, mostly via correlation with clinical pictures, which obviously constitutes shortcomings of most studies. The cortical atrophy pattern for FTD subtypes is well defined (Lindberg et al., 2009), and a diagnosis of probable FTD requires MRI or positron emission tomography (PET) findings of frontal and/or anterior temporal atrophy or hypometabolism for bvFTD (Rascovsky et al., 2011
Future directions
Improvements in the precision of the description of pathological TDP-43 subtypes in relation to clinical phenotypes have been accompanied in recent times by achievements in the detailed characterization of the molecular properties and the reliable detection of pathological TDP-43. Neurochemical marker profiles as well as imaging modalities are increasingly examined with regard to the correlation to the clinical diagnosis, to disease progression and prognosis. Also the prediction of an
Acknowledgements
This study was supported by the JPND project (Prefontals), the BMBF (FTLD consortium), the EU (Fair-park II), the Baden-Württemberg Foundation, the Thierry Latran Foundation, the ALS Association and the Boehringer Ingelheim Ulm University Bio Center (BIU). For discussion and critical reading we thank Prof M. Schöll (Gothenburg).
References (245)
- et al.
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Biochem. Biophys. Res. Commun.
(2006) - et al.
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS
Neuron
(2013) - et al.
Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis
J. Clin. Neurosci.
(2016) - et al.
Thalamic atrophy in frontotemporal dementia - not just a C9orf72 problem
NeuroImage Clin.
(2018) - et al.
Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function
FEBS Lett.
(2013) - et al.
Application of bioconjugation chemistry on biosensor fabrication for detection of TAR-DNA binding protein 43
Biosens. Bioelectron.
(2018) - et al.
Biomarkers: a new approach to behavioural variant frontotemporal dementia
Neurologia
(2015) - et al.
Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies
Neurobiol. Aging
(2018) - et al.
Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43
J. Biol. Chem.
(2010) - et al.
Single particle detection of Abeta aggregates associated with Alzheimer's disease
Biochem. Biophys. Res. Commun.
(2007)
TDP-43/FUS in motor neuron disease: complexity and challenges
Prog. Neurobiol.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Lancet Neurol.
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity
J. Biol. Chem.
Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study
Lancet Neurol.
Brain-specific cytoskeletal damage markers in cerebrospinal fluid: is there a common pattern between amyotrophic lateral sclerosis and primary progressive multiple sclerosis?
Int. J. Mol. Sci.
TDP-43 in the skin of amyotrophic lateral sclerosis patients
J. Med. Dent. Sci.
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Ann. Neurol.
Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A
Acta Neuropathol.
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies
Acta Neuropathol.
TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies
Acta Neuropathol.
Real-time quaking-induced conversion: a highly sensitive assay for prion detection
Prion
Structural determinants of the cellular localization and shuttling of TDP-43
J. Cell Sci.
Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene
Neuropathol. Appl. Neurobiol.
Neurofilament light: a candidate biomarker of pre-symptomatic ALS and phenoconversion
Ann. Neurol.
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
J. Neurol. Neurosurg. Psychiatry
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Neurology
Validating new diagnostic imaging criteria for primary progressive aphasia via anatomical likelihood estimation meta-analyses
Eur. J. Neurol.
Biomarkers for Alzheimer disease - current status and prospects for the future
J. Intern. Med.
Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia
Amyotroph. Lateral Scler. Frontotemporal Degener.
Cerebrospinal fluid TAR DNA-binding protein 43 combined with Tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders
Dement. Geriatr. Cogn. Disord.
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia
Eur. J. Nucl. Med. Mol. Imaging
Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis
J. Neurol. Neurosurg. Psychiatry
Transportin1: a marker of FTLD-FUS
Acta Neuropathol.
Axonal damage markers in cerebrospinal fluid are increased in ALS
Neurology
Stages of pTDP-43 pathology in amyotrophic lateral sclerosis
Ann. Neurol.
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Amyotroph. Lateral Scler. Other Motor Neuron Disord.
TDP-43 post-translational modifications in health and disease
Expert Opin. Ther. Targets
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease
Front. Biosci.
18F-FDG-PET correlates of cognitive impairment in ALS
Neurology
TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells
PLoS One
Comparative magnetic resonance imaging and histopathological correlates in two SOD1 transgenic mouse models of amyotrophic lateral sclerosis
PLoS One
The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia
J. Alzheimers Dis.
New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications
J. Neurol. Neurosurg. Psychiatry
Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature
Neuroepidemiology
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD
Nat. Neurosci.
Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking
EMBO J.
An acetylation switch controls TDP-43 function and aggregation propensity
Nat. Commun.
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43
Acta Neuropathol.
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype
Acta Neuropathol.
Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins
Neuropathol. Appl. Neurobiol.
Cited by (36)
TDP-43 is a potential marker of dopaminergic neuronal damage caused by atrazine exposure
2023, Ecotoxicology and Environmental SafetyTracer development for PET imaging of proteinopathies
2022, Nuclear Medicine and BiologyCitation Excerpt :Hyper-phosphorylated and ubiquitinated TDP-43 is the major component of inclusions found in ALS and some variants of FTLD [134]. The normal function of TDP-43 is to regulate gene transcription in nucleus, whereas the pathological states are marked by the TDP-43 redistribution and aggregate formation in cytoplasmic space [134]. Currently there are no TDP-43 imaging agents available.
PET imaging in dementia: Mini-review and Canadian perspective for clinical use
2024, Canadian Journal of Neurological Sciences